Tumor size and prognosis in patients with Wilms tumor

Revista Paulista de Pediatria

Valentina Oliveira Provenzi¹  Rafael Fabiano Machado Rosa¹  Rosana Cardoso Manique Rosa¹  Adriana Vial Roehe¹  Pedro Paulo Albino Dos Santos¹  Fabrízia Rennó Sodero Faulhaber¹  Ceres Andréia Vieira De Oliveira¹  Paulo Ricardo Gazzola Zen¹ 

关键词: Wilms tumor;    Organ size;    Drug therapy;    Prognosis;    Survival analysis;    Tumor de Wilms;    Tamanho do órgão;    Quimioterapia;    Prognóstico;    Análise de sobrevida;   

DOI  :  10.1016/j.rpped.2014.05.003

来源: SciELO

【 摘 要 】

OBJECTIVE: Investigate the relationship of the tumor volume after preoperative chemotherapy (TVAPQ) and before preoperative chemotherapy (TVBPQ) with overall survival at two and at five years, and lifetime. METHODS: Our sample consisted of consecutive patients evaluated in the period from 1989 to 2009 in an Onco-Hematology Service. Clinical, histological and volumetric data were collected from the medical records. For analysis, chi-square, Kaplan-Meier, log-rank and Cox regression tests were used. RESULTS: The sample consisted of 32 patients, 53.1% were male with a median age at diagnosis of 43 months. There was a significant association between TVAPQ>500mL and the difference between the TVBPQ and TVAPQ (p=0.015) and histologic types of risk (p=0.008). It was also verified an association between the difference between the TVBPQ and TVAPQ and the predominant stromal tumor (p=0.037). When assessing the TVAPQ of all patients, without a cutoff, there was an association of the variable with lifetime (p=0.013), i.e., for each increase of 10mL in TVAPQ there was an average increase of 2% in the risk of death. CONCLUSIONS: Although our results indicate that the TVAPQ could be considered alone as a predictor of poor prognosis regardless of the cutoff suggested in the literature, more studies are needed to replace the histology and staging by tumor size as best prognostic variable.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License